利用VigiBase不成比例分析进行药物重定位以发现阿尔茨海默病潜在治疗药物
本研究在WHO药物警戒数据库VigiBase中开展不成比例分析,以已用于阿尔茨海默病的抗胆碱酯酶药物的安全性特征为参照,筛选具有相似安全性特征的药物,并评估其抗胆碱酯酶活性。
要点
- VigiBase不成比例分析可筛选出安全性特征与抗胆碱酯酶药相似的候选药物。
- 氯氮平、阿立哌唑、舍曲林和S-度洛西汀在10^-5 M下对人BuChE抑制率超70%。
核心结论
- 通过药物警戒数据库的安全性特征分析,识别出4种具有阿尔茨海默病重定位潜力的药物。
- 该方法可能对未来药物重定位工作有用。
研究设计与样本
- 在WHO药物警戒数据库VigiBase中开展不成比例分析,以已用于阿尔茨海默病的抗胆碱酯酶药物为参照建立安全性特征,筛选相似药物并评估其抗胆碱酯酶活性。
主要发现
- 共识别22种安全性特征与阿尔茨海默病用药相似的药物。
- 其中4种(氯氮平、阿立哌唑、舍曲林和S-度洛西汀)在10^-5 M浓度下对人丁酰胆碱酯酶抑制率超过70%。
- 这4种药物的人丁酰胆碱酯酶半数抑制浓度值与其常规剂量下人体临床抗胆碱酯酶作用相容。
- 本研究中活性最强的人丁酰胆碱酯酶抑制剂为S-度洛西汀,半数抑制浓度为1.2 μM。
关键数值与推荐
- 安全性特征相似药物在10^-5 M浓度下对人丁酰胆碱酯酶抑制率超过70%被列为候选。
- 人丁酰胆碱酯酶半数抑制浓度值与常规剂量下临床抗胆碱酯酶作用相容作为评估依据。
临床怎么用
- 临床药学可关注氯氮平、阿立哌唑、舍曲林和S-度洛西汀在阿尔茨海默病中的重定位潜力,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Drug repositioning aims to propose new indications for marketed drugs. Although several methods exist, the utility of pharmacovigilance databases for this purpose is unclear. We conducted a disproportionality analysis in the World Health Organization pharmacovigilance database VigiBase to identify potential anticholinesterase drug candidates for repositioning in Alzheimer's disease (AD). METHODS: Disproportionality analysis is a validated method for detecting significant associations between drugs and adverse events (AEs) in pharmacovigilance databases. We applied this approach in VigiBase to establish the safety profile displayed by the anticholinesterase drugs used in AD and searched the database for drugs with similar safety profiles. The detected drugs with potential activity against acetylcholinesterase and butyrylcholinesterases (BuChEs) were then evaluated to confirm their anticholinesterase potential. RESULTS: We identified 22 drugs with safety profiles similar to AD medicines. Among these drugs, 4 (clozapine, aripiprazole, sertraline and S-duloxetine) showed a human BuChE inhibition rate of over 70% at 10-5 M. Their human BuChE half maximal inhibitory concentration values were compatible with clinical anticholinesterase action in humans at their normal doses. The most active human BuChE inhibitor in our study was S-duloxetine, with a half maximal inhibitory concentration of 1.2 μM. Combined with its ability to inhibit serotonin (5-HT) reuptake, the use of this drug could represent a novel multitarget directed ligand therapeutic strategy for AD. CONCLUSION: We identified 4 drugs with repositioning potential in AD using drug safety profiles derived from a pharmacovigilance database. This method could be useful for future drug repositioning efforts.
引用
- Chrétien B, Jourdan JP, Davis A, et al. Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease. Br J Clin Pharmacol. 2020. PMID: 33274491. doi:10.1111/bcp.14690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。